For the twelve months ended Sep 26, 2026, Charles River Laboratories International Inc. reported $3.98B of revenue and $40.19M of net income.
CRL revenue was $982.73M in fiscal Q3 2026 (ended Sep 26, 2026), down 2.2% from a year earlier and down 2.1% from the prior quarter. For the full fiscal 2025 it was $4.02B, down 0.9% from fiscal 2024. Compound annual growth was +6.5% over 5 years and +11.4% over 10 years. It rose in 8 of the last 10 fiscal years.
CRL net income was $333.07M in fiscal Q3 2026 (ended Sep 26, 2026), up 512.0% from a year earlier. For the full fiscal 2025 it was -$144.34M, compared with $22.20M in fiscal 2024.
CRL diluted EPS was $6.86 in fiscal Q3 2026 (ended Sep 26, 2026), up 523.6% from a year earlier. For the full fiscal 2025 it was -$2.91, compared with $0.20 in fiscal 2024.
CRL free cash flow was $207.28M in fiscal Q3 2026 (ended Sep 26, 2026), up 16.3% from a year earlier and up 39.5% from the prior quarter. For the full fiscal 2025 it was $518.49M, up 3.4% from fiscal 2024. Compound annual growth was +6.4% over 5 years and +7.8% over 10 years. It rose in 8 of the last 10 fiscal years.
| Line item | Dec 27, 2025 | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Dec 25, 2021 | Dec 26, 2020 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B |
| Cost of revenue | - | - | - | - | - | - | - | - | $289.67M | $277.03M |
| Gross profit | - | - | - | - | - | - | - | - | $1.57B | $1.40B |
| Selling, general and admin | $743.07M | $751.00M | $747.86M | $665.10M | $619.92M | $528.93M | $517.62M | $443.85M | $371.27M | $364.71M |
| Operating income | $25.16M | $227.35M | $617.26M | $650.98M | $589.86M | $432.73M | $351.15M | $331.38M | $288.28M | $237.55M |
| Interest expense | $107.03M | $126.29M | $136.71M | $59.29M | $73.91M | $86.43M | $60.88M | $63.77M | $29.78M | $27.71M |
| Pre-tax income | -$99.50M | $93.11M | $581.28M | $622.99M | $480.71M | $447.11M | $304.08M | $281.68M | $296.95M | $222.92M |
| Income tax | $42.66M | $67.82M | $100.91M | $130.38M | $81.87M | $81.81M | $50.02M | $54.46M | $171.37M | $66.83M |
| Net income | -$144.34M | $22.20M | $474.62M | $486.23M | $390.98M | $364.30M | $252.02M | $226.37M | $123.36M | $154.76M |
| EPS, basic | -$2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 |
| EPS, diluted | -$2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 |
| Diluted shares | 49.6M | 51.6M | 51.5M | 51.3M | 51.4M | 50.6M | 49.7M | 49.0M | 48.6M | 48.0M |
| Line item | Dec 27, 2025 | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Dec 25, 2021 | Dec 26, 2020 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $213.77M | $205.57M | $284.48M | $241.21M | $246.31M | $233.12M | $240.05M | $197.32M | $166.33M | $119.89M |
| Short-term investments | - | - | - | - | $1.06M | $1.02M | $941.0K | $885.0K | $28.49M | $3.77M |
| Receivables | $708.86M | $720.91M | $780.38M | $752.39M | $642.88M | $617.74M | $514.03M | $472.25M | $430.02M | $364.05M |
| Inventory | $299.10M | $278.54M | $380.26M | $255.81M | $199.15M | $185.69M | $160.66M | $127.89M | $114.96M | $95.83M |
| Current assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $897.84M | $826.63M | $656.83M |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $804.91M | $787.52M |
| Total assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B |
| Current liabilities | $1.12B | $994.10M | $1.06B | $1.09B | $1.03B | $839.75M | $710.18M | $558.22M | $463.50M | $429.59M |
| Short-term debt | $166.0K | $155.0K | $3.17M | $1.35M | $101.0K | $47.20M | $35.55M | $28.23M | $28.55M | $24.56M |
| Long-term debt | $2.14B | $2.24B | $2.65B | $2.71B | $2.66B | $1.93B | $1.85B | $1.64B | $1.09B | $1.19B |
| Total debt | $2.14B | $2.24B | $2.65B | $2.71B | $2.66B | $1.98B | $1.89B | $1.66B | $1.12B | $1.21B |
| Total liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B |
| Shareholders' equity | $3.16B | $3.47B | $3.60B | $2.98B | $2.54B | $2.12B | $1.64B | $1.32B | $1.05B | $839.13M |
| Line item | Dec 27, 2025 | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Dec 25, 2021 | Dec 26, 2020 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $737.65M | $734.58M | $683.90M | $619.64M | $760.80M | $546.58M | $480.94M | $441.14M | $318.07M | $316.90M |
| Capital expenditures | $219.15M | $232.97M | $318.53M | $324.73M | $228.77M | $166.56M | $140.51M | $140.05M | $82.43M | $55.29M |
| Free cash flow | $518.49M | $501.61M | $365.37M | $294.91M | $532.03M | $380.01M | $340.42M | $301.09M | $235.64M | $261.61M |
| Investing cash flow | -$209.32M | -$245.09M | -$563.15M | -$607.92M | -$1.44B | -$601.54M | -$681.50M | -$955.00M | -$72.59M | -$692.67M |
| Financing cash flow | -$536.73M | -$550.93M | -$85.52M | -$42.40M | $672.60M | $47.25M | $231.94M | $558.06M | -$208.48M | $380.76M |
| Share repurchases | $360.67M | $119.17M | $24.16M | $38.65M | $40.71M | $23.98M | $18.09M | $13.85M | $106.91M | $12.27M |
| Stock-based compensation | $71.08M | $69.89M | $72.05M | $73.62M | $71.47M | $56.34M | $57.27M | $47.35M | $44.00M | $43.64M |
| Depreciation and amortization | $403.31M | $361.74M | $314.12M | $303.87M | $265.54M | $234.92M | $198.09M | $161.78M | $131.16M | $126.66M |
| Line item | Dec 27, 2025 | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Dec 25, 2021 | Dec 26, 2020 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -0.9% | -1.9% | 3.9% | 12.3% | 21.1% | 11.5% | 15.7% | 22.0% | 10.5% | 23.3% |
| Net income growth, YoY | - | -95.3% | -2.4% | 24.4% | 7.3% | 44.6% | 11.3% | 83.5% | -20.3% | 3.7% |
| EPS growth, YoY | - | -97.8% | -2.7% | 24.7% | 5.6% | 42.0% | 9.7% | 81.9% | -21.4% | 3.2% |
| Gross margin | - | - | - | - | - | - | - | - | 84.4% | 83.5% |
| Operating margin | 0.6% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% |
| Net margin | -3.6% | 0.5% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% |
| Free cash flow margin | 12.9% | 12.4% | 8.8% | 7.4% | 15.0% | 13.0% | 13.0% | 13.3% | 12.7% | 15.6% |
| Return on equity | -4.6% | 0.6% | 13.2% | 16.3% | 15.4% | 17.2% | 15.4% | 17.2% | 11.8% | 18.4% |
| Return on assets | -2.0% | 0.3% | 5.8% | 6.4% | 5.6% | 6.6% | 5.4% | 5.9% | 4.2% | 5.7% |
| Current ratio | 1.29 | 1.41 | 1.52 | 1.32 | 1.23 | 1.43 | 1.44 | 1.61 | 1.78 | 1.53 |
| Debt to equity | 0.68 | 0.65 | 0.74 | 0.91 | 1.05 | 0.93 | 1.15 | 1.26 | 1.07 | 1.45 |
| Line item | Sep 26, 2026 | Jun 27, 2026 | Mar 28, 2026 | Dec 27, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $982.73M | $1.00B | $995.83M | $994.23M | $1.00B | $1.03B | $984.17M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B |
| Cost of revenue | - | - | - | - | - | - | - | - | $660.74M | $672.40M | $666.72M | - |
| Gross profit | - | - | - | - | - | - | - | - | $349.02M | $353.71M | $344.84M | - |
| Selling, general and admin | $140.59M | $228.90M | $159.42M | $196.14M | $177.59M | $191.55M | $177.80M | $195.71M | $199.21M | $169.79M | $186.29M | $197.14M |
| Operating income | $202.64M | $119.89M | $119.90M | -$283.44M | $133.80M | $100.13M | $74.67M | -$167.69M | $117.41M | $151.65M | $125.98M | $132.92M |
| Interest expense | $28.52M | $30.34M | $26.74M | $23.77M | $25.40M | $29.97M | $27.88M | $28.23M | $30.28M | $32.77M | $35.00M | $33.54M |
| Income tax | -$163.79M | $53.93M | -$15.14M | -$17.81M | $31.64M | $18.73M | $10.10M | -$3.04M | $20.95M | $25.39M | $24.53M | $19.75M |
| Net income | $333.07M | -$1.48M | -$14.84M | -$276.56M | $54.42M | $52.33M | $25.47M | -$214.50M | $69.66M | $94.08M | $72.96M | $187.08M |
| EPS, basic | $6.97 | -$0.03 | -$0.30 | -$5.58 | $1.11 | $1.06 | $0.50 | -$4.20 | $1.34 | $1.75 | $1.31 | $3.66 |
| EPS, diluted | $6.86 | -$0.03 | -$0.30 | -$5.57 | $1.10 | $1.06 | $0.50 | -$4.17 | $1.33 | $1.74 | $1.30 | $3.63 |
| Diluted shares | 48.6M | 48.0M | 49.0M | - | 49.4M | 49.3M | 50.9M | - | 51.6M | 51.8M | 51.8M | - |
| Line item | Sep 26, 2026 | Jun 27, 2026 | Mar 28, 2026 | Dec 27, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $200.38M | $192.03M | $191.83M | $213.77M | $207.10M | $182.82M | $229.36M | $205.57M | $210.17M | $179.21M | $327.04M | $284.48M |
| Receivables | $735.30M | $711.75M | $700.25M | $708.86M | $734.48M | $767.57M | $756.63M | $720.91M | $754.21M | $762.22M | $786.98M | $780.38M |
| Inventory | $319.64M | $346.26M | $359.72M | $299.10M | $302.55M | $279.55M | $290.16M | $278.54M | $336.20M | $349.11M | $361.28M | $380.26M |
| Current assets | $1.54B | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | $1.61B |
| Goodwill | $3.08B | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | $3.10B |
| Total assets | $7.45B | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | $8.20B |
| Current liabilities | $1.09B | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994.10M | $1.01B | $947.52M | $954.81M | $1.06B |
| Short-term debt | $2.10M | $5.46M | $6.70M | $166.0K | $54.0K | $98.0K | $121.0K | $155.0K | $157.0K | $435.0K | $459.0K | $3.17M |
| Long-term debt | $2.44B | $2.62B | $2.66B | $2.14B | $2.19B | $2.33B | $2.51B | $2.24B | $2.33B | $2.41B | $2.66B | $2.65B |
| Total debt | $2.45B | $2.63B | $2.67B | $2.14B | $2.19B | $2.33B | $2.51B | $2.24B | $2.33B | $2.41B | $2.66B | $2.65B |
| Total liabilities | $4.18B | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | $4.54B |
| Shareholders' equity | $3.23B | $2.85B | $2.95B | $3.16B | $3.41B | $3.36B | $3.20B | $3.47B | $3.79B | $3.73B | $3.65B | $3.60B |
| Line item | Sep 26, 2026 | Jun 27, 2026 | Mar 28, 2026 | Dec 27, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $254.09M | $179.72M | $41.08M | $147.52M | $213.83M | $204.60M | $171.70M | $159.36M | $251.79M | $193.53M | $129.89M | $220.94M |
| Capital expenditures | $46.81M | $31.11M | $55.91M | $88.95M | $35.58M | $35.30M | $59.32M | $75.62M | $38.72M | $39.49M | $79.14M | $78.32M |
| Free cash flow | $207.28M | $148.62M | -$14.83M | $58.57M | $178.25M | $169.31M | $112.37M | $83.75M | $213.07M | $154.05M | $50.74M | $142.62M |
| Investing cash flow | $10.23M | $28.10M | -$407.85M | -$92.81M | -$33.70M | -$37.34M | -$45.48M | -$76.10M | -$21.32M | -$61.87M | -$85.79M | -$238.37M |
| Financing cash flow | -$254.15M | -$164.66M | $347.72M | -$51.86M | -$152.62M | -$226.92M | -$105.33M | -$75.88M | -$207.54M | -$285.86M | $18.35M | $123.57M |
| Share repurchases | $224.0K | $115.60M | $208.28M | $96.0K | $93.0K | $7.35M | $353.13M | $124.0K | $100.79M | $8.91M | $9.35M | $139.0K |
| Stock-based compensation | $20.77M | $19.78M | $22.38M | $17.63M | $23.27M | $17.05M | $13.13M | $17.23M | $19.33M | $16.59M | $16.74M | $19.52M |
| Depreciation and amortization | $72.26M | $67.29M | $67.15M | $78.28M | $85.16M | $119.51M | $120.36M | $102.10M | $88.20M | $86.08M | $85.36M | $80.51M |
| Line item | Sep 26, 2026 | Jun 27, 2026 | Mar 28, 2026 | Dec 27, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -2.2% | -2.7% | 1.2% | -0.8% | -0.5% | 0.6% | -2.7% | -1.1% | -1.6% | -3.2% | -1.7% | -7.9% |
| Net income growth, YoY | 512.0% | - | - | - | -21.9% | -44.4% | -65.1% | - | -20.3% | -3.0% | -29.3% | -0.2% |
| EPS growth, YoY | 523.6% | - | - | - | -17.3% | -39.1% | -61.5% | - | -21.3% | -7.9% | -35.3% | -0.8% |
| Gross margin | - | - | - | - | - | - | - | - | 34.6% | 34.5% | 34.1% | - |
| Operating margin | 20.6% | 11.9% | 12.0% | -28.5% | 13.3% | 9.7% | 7.6% | -16.7% | 11.6% | 14.8% | 12.5% | 13.1% |
| Net margin | 33.9% | -0.1% | -1.5% | -27.8% | 5.4% | 5.1% | 2.6% | -21.4% | 6.9% | 9.2% | 7.2% | 18.5% |
| Free cash flow margin | 21.1% | 14.8% | -1.5% | 5.9% | 17.7% | 16.4% | 11.4% | 8.4% | 21.1% | 15.0% | 5.0% | 14.1% |
| Current ratio | 1.41 | 1.35 | 1.36 | 1.29 | 1.37 | 1.36 | 1.43 | 1.41 | 1.48 | 1.58 | 1.75 | 1.52 |
| Debt to equity | 0.76 | 0.92 | 0.91 | 0.68 | 0.64 | 0.69 | 0.78 | 0.65 | 0.61 | 0.65 | 0.73 | 0.74 |
Source: XBRL data Charles River Laboratories International Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CRL | $3.98B | -1.2% | $40.19M | 1.0% | $16.17B |
| IQV | $17.31B | +8.8% | $1.40B | 8.1% | $44.80B |
| INCY | $6.01B | +24.9% | $403.41M | 6.7% | $24.39B |
| MEDP | $2.84B | +20.4% | $517.83M | 18.2% | $18.27B |
| ICLR | $8.25B | +0.8% | $229.34M | 2.8% | $15.68B |
| ABSI | $1.56M | -62.3% | -$121.08M | -7756.4% | $1.75B |
| OABI | $40.21M | +90.6% | -$43.47M | -108.1% | $732.9M |
| NRC | $143.79M | +3.4% | $6.13M | 4.3% | $548.7M |
| MXCT | $31.05M | -13.2% | -$35.64M | -114.8% | $130.0M |